Zhang S-J, Qian H-N, Zhao Y, Sun K, Wang H-Q, Liang G-Q, et al. Relationship between age and prostate size. Asian J Androl 2013;15:116–20.
Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E. et al. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging.male (MSAM-7). Prog Urol. 2004;14:332–44.
Egan KB, Burnett AL, McVary KT, Ni X, Suh M, Wong DG, et al. The Co-occurring Syndrome—Coexisting Erectile Dysfunction and Benign Prostatic Hyperplasia and Their Clinical Correlates in Aging Men: Results From the National Health and Nutrition Examination Survey. Urology 2015;86:570–80.
Lusty A, Siemens DR, Tohidi M, Whitehead M, Tranmer J, Nickel JC. Cardiac Failure Associated with Medical Therapy of Benign Prostatic Hyperplasia: A Population Based Study. J Urol. 2021;205:1430–7.
Nguyen D-D, Herzog P, Cone EB, Labban M, Zorn KC, Chughtai B, et al. Disproportional signal of sexual dysfunction reports associated with finasteride use in young men with androgenetic alopecia: A pharmacovigilance analysis of VigiBase. J Am Acad Dermatol. 2023;88:179–81.
Article CAS PubMed Google Scholar
Nguyen D-D, Marchese M, Cone EB, Paciotti M, Basaria S, Bhojani N, et al. Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. JAMA Dermatol. 2021;157:35–42.
Cindolo L, Fanizza C, Romero M, Pirozzi L, Autorino R, Berardinelli F, et al. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis. World J Urol. 2013;31:665–71.
Sugianto R, Tirtayasa PMW, Duarsa GWK. A comprehensive review of medical therapy on benign prostatic hyperplasia. Sexologies 2022;31:52–60.
Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S, Montorsi F, et al. Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Enlargement. Eur Urol 2010;58:384–97.
Bouhadana D, Nguyen D-D, Raizenne B, Schwarcz J, Gordon H, Chughtai B, et al. Evaluating the acceptability of an online patient decision aid for the surgical management of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Can Urol Assoc J. 2021;15:247–54.
Article PubMed PubMed Central Google Scholar
Malde S, Umbach R, Wheeler JR, Lytvyn L, Cornu J-N, Gacci M, et al. A Systematic Review of Patients’ Values, Preferences, and Expectations for the Diagnosis and Treatment of Male Lower Urinary Tract Symptoms. Eur Urol. 2021;79:796–809.
Bouhadana D, Nguyen D-D, Zorn KC, Elterman DS, Bhojani N. Patient perspectives on benign prostatic hyperplasia surgery: A focus on sexual health. J Sex Med. 2020;17:2108–12.
Sadri I, Arezki A, Couture F, Nguyen D-D, Schwartz R, Zakaria AS, et al. Reasons to overthrow TURP: Bring on Aquablation. World J Urol. 2021;39:2291–9.
Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. J Urol. 2018;199:1252–61.
Desai M, Bidair M, Bhojani N, Trainer A, Arther A, Kramolowsky E, et al. WATER II (80-150 mL) procedural outcomes. BJU Int. 2019;123:106–12.
Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART II-Surgical Evaluation and Treatment. J Urol. 2021;206:818–26.
Elterman D, Aubé-Peterkin M, Evans H, Elmansy H, Meskawi M, Zorn KC, et al. UPDATE – 2022 Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH). Canadian Urol Assoc J. 2022;16. https://doi.org/10.5489/cuaj.7906.
Management of Non-neurogenic Male LUTS. Uroweb - European Association of Urology. https://uroweb.org/guidelines/management-of-non-neurogenic-male-luts/chapter/disease-management (accessed 3 Jan 2023).
Nguyen D-D, Barber N, Bidair M, Gilling P, Anderson P, Zorn KC, et al. Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue trial (WATER) vs WATER II: comparing Aquablation therapy for benign prostatic hyperplasia in 30-80 and 80-150 mL prostates. BJU Int. 2020;125:112–22.
Bhojani N, Nguyen D-D, Kaufman RP Jr., Elterman D, Zorn KC. Comparison of 100 cc prostates undergoing aquablation for benign prostatic hyperplasia. World J Urol. 2019;37:1361–8.
Article CAS PubMed Google Scholar
Nguyen D-D, Mantri SS, Zorn KC, Misraï V, Elterman D, Bhojani N. Which anatomic structures should be preserved during aquablation contour planning to optimize ejaculatory function? A case-control study using ultrasound video recordings to identify surgical predictors of postoperative anejaculation. Urology. 2021;153:250–5.
Elterman D, Bach T, Rijo E, Misrai V, Anderson P, Zorn KC, et al. Transfusion rates after 800 Aquablation procedures using various haemostasis methods. BJU Int. 2020;125:568–72.
Article PubMed PubMed Central Google Scholar
MacRae C, Gilling P. How I do it: Aquablation of the prostate using the AQUABEAM system. Can J Urol. 2016;23:8590–3.
El Hajj A, Misrai V, Nasrallah AA, Labban ML, Najdi JA, Rijo E. Learning curve in aquablation: an international multicenter study. World J Urol. 2022;40:773–9.
Nguyen D-D, Misraï V, Bach T, Bhojani N, Lingeman JE, Elterman DS, et al. Operative time comparison of aquablation, greenlight PVP, ThuLEP, GreenLEP, and HoLEP. World J Urol. 2020;38:3227–33.
Bach T, Giannakis I, Bachmann A, Fiori C, Gomez-Sancha F, Herrmann TRW, et al. Aquablation of the prostate: single-center results of a non-selected, consecutive patient cohort. World J Urol. 2019;37:1369–75.
Article CAS PubMed Google Scholar
Bach T, Gilling P, El Hajj A, Anderson P, Barber N. First Multi-Center All-Comers Study for the Aquablation Procedure. J Clin Med Res. 2020;9. https://doi.org/10.3390/jcm9020603.
Elterman D, Gilling P, Roehrborn C, Barber N, Misrai V, Zorn KC, et al. Meta-analysis with individual data of functional outcomes following Aquablation for lower urinary tract symptoms due to BPH in various prostate anatomies. BMJ Surg Inter Health Technol. 2021;3:e000090.
Assad A, Nguyen D-D, Barber N, Bidair M, Gilling P, Anderson P, et al. WATER vs WATER II 3-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30-80 cc and 80-150 cc Prostates. Urology. 2022;165:268–74.
Nguyen D-D, Barber N, Bidair M, Gilling P, Anderson P, Zorn KC, et al. WATER versus WATER II 2-Year Update: Comparing Aquablation Therapy for Benign Prostatic Hyperplasia in 30-80-cm and 80-150-cm Prostates. Eur Urol Open Sci. 2021;25:21–28.
Article PubMed PubMed Central Google Scholar
Gilling PJ, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. Five-year outcomes for Aquablation therapy compared to TURP: results from a double-blind, randomized trial in men with LUTS due to BPH. Can J Urol. 2022;29:10960–8.
Bhojani N. Aquablation for benign prostatic hyperplasia in large prostates (80-150cc): 4-year results. Eur Urol. 2022;81:S1313–S1314.
Bhojani N, Yafi FA, Misrai V, Rijo E, Chughtai B, Zorn KC, et al. Review of Sexual Preservation After Novel Benign Prostatic Hyperplasia Surgical Treatment Modalities From Food and Drug Administration Clinical Trials. Sex Med Rev. 2021;9:169–73.
Zorn KC, Bidair M, Trainer A, Arther A, Kramolowsky E, Desai M, et al. Aquablation therapy in large prostates (80-150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial results. BJUI Compass. 2022;3:130–8.
McVary KT, Gittelman MC, Goldberg KA, Patel K, Shore ND, Levin RM, et al. Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. J Urol. 2021;206:715–24.
McVary KT, El-Arabi A, Roehrborn C. Preservation of sexual function 5 years after water vapor thermal therapy for benign prostatic hyperplasia. Sex Med. 2021;9:100454.
Article PubMed PubMed Central Google Scholar
Dixon CM, Rijo Cedano E, Mynderse LA, Larson TR. Transurethral convective water vapor as a treatment for lower urinary tract symptomatology due to benign prostatic hyperplasia using the Rezūm(®) system: evaluation of acute ablative capabilities in the human prostate. Res Rep Urol. 2015;7:13–18.
PubMed PubMed Central Google Scholar
Arezki A, Sadri I, Couture F, Schwartz R, Nguyen D-D, Zakaria AS, et al. Reasons to go for Rezūm steam therapy: an effective and durable outpatient minimally invasive procedure. World J Urol. 2021;39:2307–13.
Woo HH, Gonzalez RR. Perspective on the Rezūm System: A minimally invasive treatment strategy for benign prostatic hyperplasia using convective radiofrequency water vapor thermal therapy. Med Devices. 2017;10:71–80.
Gauhar V, Lim EJ, Khan TY, Law YXT, Choo ZW, Castellani D, et al. Rezum to the rescue: Early outcomes of Rezum on patients with recurrent lower urinary tract symptoms after surgical interventions for benign prostatic enlargement. Andrologia. 2022; 54. https://doi.org/10.1111/and.14450.
Elterman D, Bhojani N, Vannabouathong C, Chughtai B, Zorn KC. Rezūm therapy for ≥ 80‐ mL benign prostatic enlargement: a large, multicentre cohort study. BJU Int. 2022;130:522–7.
Article CAS PubMed Google Scholar
Elterman D, Bhojani N, Vannabouathong C, Chughtai B, Zorn KC. Large, multi-center, prospective registry of rezūm water vapor therapy for benign prostatic hyperplasia. Urology. 2022;165:261–7.
留言 (0)